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Abstract
Sarcomas are a key feature of Li-Fraumeni and related syndromes (LFS/LFL), associated with germline TP53 mutations.
Current penetrance estimates for TP53 mutations are subject to significant ascertainment bias. The International Sarcoma
Kindred Study is a clinic-based, prospective cohort of adult-onset sarcoma cases, without regard to family history. The entire
cohort was screened for mutations in TP53 using high-resolution melting analysis and Sanger sequencing, and multiplex-
ligation-dependent probe amplification and targeted massively parallel sequencing for copy number changes. Pathogenic
TP53 mutations were detected in blood DNA of 20/559 sarcoma probands (3.6%); 17 were germline and 3 appeared to be
somatically acquired. Of the germline carriers, one appeared to be mosaic, detectable in the tumor and blood, but not
epithelial tissues. Germline mutation carriers were more likely to have multiple cancers (47% vs 15% for non-carriers,
P= 3.061023), and earlier cancer onset (33 vs 48 years, P= 1.1961023). The median survival of mutation carriers following
first cancer diagnosis was not significantly different from non-carriers. Only 10/17 (59%) pedigrees met classical or Chompret
criteria for LFS. In summary, germline TP53 mutations are not rare in adult patients with sarcoma, with implications for
screening, surveillance, treatment and genetic counselling of carriers and family members.
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Introduction
Germline TP53 mutations result in the classical Li-Fraumeni or
Li-Fraumeni-like syndromes (LFS/LFL) [1], rare inherited
syndromes with a lifetime cancer penetrance up to 73% for males
and ,100% for females[2–7]. Historically there has been little
enthusiasm in the medical community for germline TP53 testing in
LFS/LFL. Reasons include the perceptions of rarity, a lack of
proven risk management strategies, and the potential for
psychological harm by identifying people with an unmodifiable,
extreme cancer risk [8]. However, developments in breast and
whole body MRI screening [9,10], pre-implantation genetic
diagnosis for family planning, and the use of genetic information
to guide cancer therapy, may influence decision-making for TP53
genetic testing.
Mutation frequencies and penetrance estimates are largely
derived from pedigree-ascertained pediatric, cohorts[4–6,8,11],
fraught with ascertainment biases. Moreover, studies of LFS-
associated cancers[12–16] suggest many germline TP53 mutation
carriers have little family history, or will be increasingly identified
through genomic screens of cancer populations unselected for
family history. Accurate risk counselling to the carriers identified
in these ways will require study of the impact of TP53 mutations
outside of familial settings.
Sarcomas are the most common cancer type seen in LFS [17];
approximately 90% of sarcomas occur in adults [18]. To determine
the incidence and clinical spectrum of germline TP53 mutations in
adult-onset sarcoma populations, a systematic screen using multi-
plexed ligation-dependent probe amplification and Sanger sequenc-
ing was undertaken in 559 probands consecutively recruited from
adult sarcoma clinics–agnostic to family history–on the Australian




Pathogenic or putatively pathogenic TP53 events occurred in
the peripheral blood DNA of 20/559 probands (3.6%), comprising
18 single nucleotide mutations or indels, and 2 whole gene
deletions (Table 1). Pathogenicity was assigned as described in the
Materials and Methods, and in Figure S1. Most were previously
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reported somatically [19], but 10 are reported here for the first
time in the germline. Six variants were regarded as putatively
pathogenic. The age of sarcoma onset in individuals carrying
pathogenic variants was not significantly different from those
carrying putatively pathogenic variants (mean6standard devia-
tion: 38617 years versus 40619 years, compared to 48618 years
for non-carriers in the ISKS cohort). Seventeen were putative
germline events, with the mutant allele also detected in tumor
DNA and 8 tumors also demonstrating loss of heterozygosity. The
remaining 3 cases suggested somatic origin: Case 18 had clinical
evidence of myelodysplasia (MDS), and neither parent carried the
TP53 mutation. Both cases 19 and 20 demonstrated heterozygous
whole gene deletion. While neither cases 19 or 20 had clinical
evidence of MDS, both cases 18 and 19 showed widespread copy
number changes in the peripheral blood–including the RB1 locus
in case 19–suggestive of somatic tumor changes rather than
germline events. Only case 18 had been exposed to chemotherapy
prior to blood sampling.
Ten of 17 (59%) germline carriers had classical LFS or
Chompret pedigrees that would have prompted genetic testing
(Table 2). Case 14 showed somatic mosaicism, with 20–25% of
mutant alleles (estimated by both Sanger sequencing and HRM
analysis) in the peripheral blood, heterozygosity in the tumor, and
absent in adjacent buccal mucosa (Figure 1). Somatic mosaicism
for TP53 mutations has been previously reported [20]. Of the
putatively pathogenic variants, 1 occurred in a family fitting
classical Li-Fraumeni criteria (case 4); two occurred in individuals
fitting Chompret criteria (cases 6 & 8), and three did not
demonstrate an unusual family history of cancer (cases 14, 16 &
17). This pattern is not meaningfully different than carriers of
pathogenic variants.
Regardless of family history, carriers of TP53 mutations
appeared at increased personal risk for cancer. The median age
of onset (6standard deviation) of first cancer in the germline TP53
probands was 33614yrs compared to 48618yrs in non-carriers
(Student’s unpaired 2-tailed t-test P=1.1961023), and the median
age at first sarcoma was 36617yrs vs 50618yrs (P=4.3361023)
(Table 3). Eight of 17 mutation carriers had multiple primary
cancers (Table 2), three occurring within prior radiation fields.
Mutation carriers had an increased incidence of multiple cancers
(47% versus 15% of non-carriers, Fisher’s exact test 2-tailed
P=3.061023). With a short median follow up of 20 months, the
survival of carriers in the ISKS cohort from first cancer diagnosis
was not significantly different from non-carriers (Hazard ratio
1.175, 95% CI 0.44–3.12, Mantel-Cox P=0.75). To investigate a
possible survival bias, we also analysed those cases newly
diagnosed with sarcoma during the period of recruitment from
2007 onwards (Figure 2). Again, the survival of carriers again was
not significantly different to non-carriers (Hazard ratio 1.02, 95%
CI 0.36–2.89, Mantel-Cox P=0.97). Excluding probands, the
median age at first cancer onset in TP53 mutation positive families
was 54622yrs versus 60618yrs in TP53 negative families
(P=9.361023). As recently reported in the IARC TP53 database
[18], more leiomyosarcoma and undifferentiated pleomorphic
sarcomas were seen compared to previous reports in pediatric
populations [3,21].
Figure 1. Somatic mosaicism demonstrated in an ISKS proband. Case 14 presented with an osteosarcoma of the mandible at age 19yrs. HRM
analysis of the peripheral blood DNA estimated that 20–25% of alleles were mutant. The mutation was detected in tumour DNA and found to be
heterozygous, but was absent in multiple other non-tumour tissues of the mouth.
doi:10.1371/journal.pone.0069026.g001
Figure 2. Kaplan-Meier overall survival analysis comparing
TP53 mutation carriers to non-carriers. To correct for survival bias,
this analysis was limited to ISKS participants prospectively recruited
from 2007 onwards (TP53 mutation carriers, n = 11; Non-carriers,
n = 420).
doi:10.1371/journal.pone.0069026.g002
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Discussion
The germline mutation rate observed in the ISKS cohort (3%)
matches the 2–4% [12], [21] in childhood osteosarcoma, 2–3%
reported in early onset breast cancer [15,22], but is less than
reported for choroid plexus carcinomas (44%) [14]. Only 60% of
carriers had a family history potentially recognisable as associated
with germline TP53 mutations. One mutation is clearly due to
somatic mosaicism. Assuming a 20% new mutation rate [3,6], the
penetrance of the remaining mutations may account for the lack of
a strong family history [3].
The identification of somatic and mosaic mutations remind us
that peripheral blood is only a surrogate for the germline. Somatic
TP53 mutations are common in hematologic cancers, and cancer-
prone individuals may harbour preclinical genetic evidence of
dysplasia even in apparently normal blood. This differentiates
TP53 testing from genes such as BRCA1/2 or the mismatch repair
genes, which appear rarely somatically mutated in hematologic
malignancy. Prior mutagen exposure, including chemotherapy,
may be important. It is clinically important to confirm the
presence of putative germline TP53 mutations in more than one
tissue, including the tumor tissue.
These results challenge nihilistic perceptions regarding germline
TP53 mutation incidence, cancer risk and survival [23,24]. As
genomic technologies are increasingly applied to cancer cohorts,
regardless of clinical or family history, more TP53 mutation
carriers will be identified and require counselling and care from
their medical supports. Interpretation of purely genotypic infor-
mation is difficult using data mostly ascertained on clinical or
familial criteria. While more common than expected, the outlook
for TP53 mutation carriers with sarcoma appears comparable to
non-carriers, and options are emerging for cancer screening [10],
family planning [25], and the selection of less carcinogenic cancer
treatments. Continued research into germline TP53 mutations is
critical to understanding the impact of these mutations on cancer
treatments and outcomes, and to develop effective cancer
screening strategies for our patients and their families.
Materials and Methods
International Sarcoma Kindred Study (ISKS)
ISKS is a clinic-based prospective cohort of adult-onset sarcoma
cases and families aimed to investigate the hereditary aspects of
this disease. Probands (n = 559, 54% male) were consecutively
recruited from 6 major sarcoma treatment centres across
Australia. Probands over 14 years of age with a histologically
confirmed sarcoma (64% soft tissue, 36% bone subtypes) were
consented to donation and use of biospecimens and provided
family history information. Medical history and treatment records
were obtained for each proband where possible. All reported
cancer diagnoses were independently verified by reference to the
medical records, Australian and New Zealand cancer registries or
death certificates. Study questionnaires containing demographic,
medical, epidemiological and psychosocial information were
completed, including personal history of cancer or exposure to
known risk factors for sarcoma. Self-reported ethnicity was 84%
Table 2. Proband cancers and clinical classification.




1 M rhabdomyosarcoma 33 LFS
2 M osteosarcoma 20 LFS
3 M chondrosarcoma 24; liposarcoma 39 LFS
4 M sarcoma NOS 37; liposarcoma 44 LFS
5 F angiosarcoma 25 Chomp LFL
6 F breast 33; leiomyosarcoma 48 Chomp LFL
7 F breast 38; leiomyosarcoma 45; thyroid 46 Chomp LFL
8 F ALL 10; Ewing sarcoma 16 Chomp LFL
9 F breast 26; sarcoma NOS 36; pheochromocytoma 37 Chomp LFL
10 M Hodgkin’s lymphoma 34; melanoma 47; sarcoma NOS 60 Chomp LFL
11 M DSRCT 21 Negative
12 M testis 36; rectum 69; leiomyosarcoma 69 Negative
13 F chondrosarcoma 57 Negative
14 M osteosarcoma 19 Negative
15 M osteosarcoma 31 Negative
16 F leiomyosarcoma 58 Negative
17 F liposarcoma 62 Negative
Putative somatic
18 M mediastinal GCT with rhabdomyosarcomatous differentiation 19 Chomp LFL
19 M GIST 65; melanoma 69; sarcoma NOS 76; mycosis fungoides 76 Negative
20 F sarcoma NOS 80 Negative
ALL, acute lymphoblastic leukemia; DSRCT, desmoplastic small round cell tumour; GCT, germ cell tumour; GIST, gastrointestinal stromal tumour; Chomp, Chompret; M,
male; F, female.
doi:10.1371/journal.pone.0069026.t002
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Caucasian, 4% Chinese or South East Asian, 3% unknown, with
the remainder from diverse ethnic backgrounds.
Clinical Classification of Families
Pedigrees to at least second degree relatives of the proband were
classified according to a recognised set of clinical criteria[1,26–29].
A family history was considered positive if the classical LFS or
Chompret LFS criteria were met.
Biospecimen Processing
Anti-coagulated blood was processed using a Ficoll gradient.
DNA was extracted from the nucleated cell product using
QIAamp DNA blood kit (Qiagen, Germany).
After micro-dissection of tumour material from formalin fixed
paraffin embedded tissue, DNA was extracted using DNeasy tissue
kit (Qiagen, Germany) as described previously [30].
TP53 HRM Screening
High resolution melt (HRM) analysis was used to screen for
mutations in exons 2–11 of the TP53 gene. PCR and HRM were
performed on the LightCycler 480 (Roche Diagnostics, Australia).
The reaction mixture included 16 PCR buffer, 2.5 mM MgCl2,
200 nM of each primer, 200 mM of dNTPs, 5 mM of Syto 9
(Invitrogen, Carlsbad, CA), 0.5 U of HotStarTaq polymerase
(Qiagen, Valencia, CA), 10 ng DNA and PCR grade water in a
total volume of 10 mL. PCR conditions included an activation step
of 15 minutes at 95uC followed by 55 cycles of 95uC for 10
seconds, annealing for 10 seconds comprising 10 cycles of a
touchdown from 65 to 55uC at 1uC/cycle followed by 35 cycles at
55uC, and extension at 72uC for 30 seconds; one cycle of 95uC for
1 minute, 45uC for 1 minute and a HRM step from 72 to 95uC
rising at 0.02uC per second. Primers for all exons are shown in
Table S1. The primers used for HRM analysis for exons 6–8 were
those published in Krypuy et al [31] with the exception of the exon
6 reverse primer. For both exons 4 and 5, a set of three amplicons
were designed to span the coding region of each exon.
All analyses were performed in duplicate. At least five different
normal controls were included in each run. Where possible, a
positive control sample was included for each amplicon. Samples
showing an aberrant melt profile compared to normal controls via
HRM were directly sequenced from a 1/10 dilution of the HRM
product using the BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA) according to the manufac-
turer’s instructions.
Variants were triaged for pathogenicity as follows (see Figure
S1). Variants were defined as pathogenic if previously reported to
be associated with Li-Fraumeni syndrome in the IARC TP53
database (R16, accessed February 2013), or they resulted in a
frameshift, premature stop codon, or affected an essential splice
site. Variants were considered putatively pathogenic those variants
which have either been reported somatically mutated more than 5
times in the IARC database, or which were predicted to be
pathogenic by Condel, or both. In all but one case (R333C), both
criteria were satisfied. R333C was included because a known
pathogenic variant (R337H) is located in the same region (the
tetramerization domain of TP53), and has been reported to result
in loss of function by Kato et al [32].
TP53 LOH Testing
For LOH analysis, tumour and matching normal DNA were
amplified and sequenced. Evidence for any LOH was only
inferred if the strength of the WT allele was reduced by at least
50% on the sequencing trace in tumour DNA compared to
matching normal DNA.
Mutilplex Ligation-dependent Probe Amplification
(MLPA)
Large deletions or genomic rearrangements of patients were
analyzed by a commercial MLPA kit (SALSA MLPA probemix
P056-B1 TP53, MRC Holland, Amsterdam, The Netherlands)
according to the manufacturer’s instructions. DNA (100 ng)
extracted from peripheral blood was used with a normal and





Male 9 (53%) 291 (54%)
Female 8 (47%) 248 (46%)
Median age at diagnosis (yrs6SD)











Osteosarcoma 3 (16%) 52 (10%)
Chondrosarcoma 2 (11%) 48 (9%)
Ewing/Primitive neuroectodermal tumour 1 (5%) 47 (9%)
Other – 3 (1%)
Soft tissue
Undifferentiated pleomorphic sarcoma 3 (16%) 67 (12%)
Leiomyosarcoma 4 (21%) 61 (11%)
Fibromyxosarcoma – 51 (9%)
Well differentiated/Dedifferentiate LPS 1 (5%) 43 (8%)
Myxoid LPS – 27 (5%)
LPS not otherwise specified 2 (11%) 14 (3%)
Synovial sarcoma – 38 (7%)
Angiosarcoma 1 (5%) 8 (1%)
Epithelioid sarcoma – 8 (1%)
Malignant peripheral nerve sheath tumour – 8 (1%)
Rhabdomyosarcoma 1 (5%) 7 (1%)
Desmoplastic small round cell tumour 1 (5%) –
Other – 64 (12%)
Family history
Classic Li Fraumeni Syndrome 4 (24%) 4 (,1%)
Chompret Li Fraumeni Like 6 (35%) 44 (8%)
Other familial cancer syndrome – 8 (1%)
No family history 7 (41%) 458 (85%)
Uninformative – 25 (5%)
*some probands have .1 sarcoma; SD, standard deviation; LPS, liposarcoma.
doi:10.1371/journal.pone.0069026.t003
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positive control sample included in every assay. MLPA PCR
products were separated on the ABI3730 instrument (Applied
Biosystems) and peak heights for each PCR product were
compared to a normal sample using GeneMarker software to
determine gene dosage for each individual exon. Every positive
result was repeated at least twice.
The two cases with whole gene deletion were verified by using
custom exon capture using Haloplex reagents (Agilent Technol-
ogies, Inc., Santa Clara, CA). Custom capture reagents were
designed including the entire gene for TP53, as well as coding
exons for 84 additional genes including RB1. Copy number states
for all loci were inferred from SNP allelic ratios and the CONTRA
algorithm for identifying copy-number gains and losses using
fluctuations in sequencing read depth [33]. Target regions were
divided into 100 bp bins for the CONTRA analysis, to adjust for
the limited number of target regions and deep read coverage of the
custom capture.
Statistical Analyses
Statistical analyses of age at cancer diagnosis were performed
using a Student’s unpaired two-tailed t-test with unequal variance,
and where appropriate a Fisher’s exact test. Survival analyses used
a Log-rank (Mantel-Cox) test for survival comparisons.
Ethics Statement
This project was conducted under the auspices of the human
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